Literature DB >> 1627564

Binding specificities of actinomycin D to non-self-complementary -XGCY-tetranucleotide sequences.

F M Chen1.   

Abstract

Studies on the binding specificity of actinomycin D (ACTD) to tetranucleotide sequences of the form -XGCY- have been extended to include the non-self-complementary sequences. ACTD binding characteristics are investigated by equilibrium, kinetic, and thermal denaturation for decameric duplexes d(ATA-XGCY-ATA)-d(TAT-Y'GCX'-TAT), where X and Y are complementary to X' and Y', respectively, but not to each other. The results indicate that when X = G or Y = C, the oligomers exhibit significantly weaker ACTD binding affinities, smaller melting temperature increases upon drug binding, and faster SDS-induced ACTD dissociation rates than the other sequences. Estimated binding constants at 18.5 degrees C for decameric duplexes containing -AGCA-/-TGCT-, -AGCG-/-CGCT-, or -CGCA-/-TGCG- are in the range of 4-9 microM-1, whereas for the ones containing -GGCT-/-AGCC-, -GGCA-/-TGCC-, or -GGCG-/-CGCC- they range from 0.6 to 2 microM-1. In contrast to the characteristic SDS-induced ACTD dissociation times of 600-1000 s for the stronger binding sites, the sequences containing X = G or Y = C exhibit at least an order of magnitude faster dissociation kinetics. These observations are further supported by the induced CD results and fluorescence measurements with 7-amino-ACTD. The findings from these non-self-complementary -XGCY- tetranucleotide sequences are consistent with those found earlier for the self-complementary counterparts, and they together clearly demonstrate that a base sequence alteration adjacent to the GC site can have a profound effect on the ACTD binding as well as dissociation characteristics, likely a consequence of subtle conformational alterations near the binding site.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1627564     DOI: 10.1021/bi00142a008

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  Actinomycin D binds strongly to d(CGACGACG) and d(CGTCGTCG).

Authors:  F Sha; F M Chen
Journal:  Biophys J       Date:  2000-10       Impact factor: 4.033

2.  Structure-affinity relationships for the binding of actinomycin D to DNA.

Authors:  J Gallego; A R Ortiz; B de Pascual-Teresa; F Gago
Journal:  J Comput Aided Mol Des       Date:  1997-03       Impact factor: 3.686

3.  Solution structure of the ActD-5'-CCGTT3GTGG-3' complex: drug interaction with tandem G.T mismatches and hairpin loop backbone.

Authors:  Ko-Hsin Chin; Fu-Ming Chen; Shan-Ho Chou
Journal:  Nucleic Acids Res       Date:  2003-05-15       Impact factor: 16.971

4.  Unique actinomycin D binding to self-complementary d(CXYGGCCY'X'G) sequences: duplex disruption and binding to a nominally base-paired hairpin.

Authors:  Fu-Ming Chen; Feng Sha; Ko-Hsin Chin; Shan-Ho Chou
Journal:  Nucleic Acids Res       Date:  2003-07-15       Impact factor: 16.971

5.  Visualising the kinetics of dissociation of actinomycin from individual sites in mixed sequence DNA by DNase I footprinting.

Authors:  M C Fletcher; K R Fox
Journal:  Nucleic Acids Res       Date:  1993-03-25       Impact factor: 16.971

6.  Binding of actinomycin D to single-stranded DNA of sequence motifs d(TGTCT(n)G) and d(TGT(n)GTCT).

Authors:  Fu-Ming Chen; Feng Sha; Ko-Hsin Chin; Shan-Ho Chou
Journal:  Biophys J       Date:  2003-01       Impact factor: 4.033

7.  From dynamic combinatorial 'hit' to lead: in vitro and in vivo activity of compounds targeting the pathogenic RNAs that cause myotonic dystrophy.

Authors:  Leslie O Ofori; Jason Hoskins; Masayuki Nakamori; Charles A Thornton; Benjamin L Miller
Journal:  Nucleic Acids Res       Date:  2012-04-06       Impact factor: 16.971

8.  Study of interactions between actinomycin D and oligonucleotides by microchip electrophoresis and ESI-MS.

Authors:  Xiaomian Zhou; Zheng Shen; Dazhi Li; Xinya He; Bingcheng Lin
Journal:  Talanta       Date:  2006-12-21       Impact factor: 6.057

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.